Androgenic Alopecia - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Androgenic Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 4 and 1 respectively.

Androgenic Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Androgenic Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Androgenic Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Androgenic Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Androgenic Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Androgenic Alopecia (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Androgenic Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Androgenic Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Androgenic Alopecia Overview 7
Therapeutics Development 8
Pipeline Products for Androgenic Alopecia - Overview 8
Androgenic Alopecia - Therapeutics under Development by Companies 9
Androgenic Alopecia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Androgenic Alopecia - Products under Development by Companies 13
Androgenic Alopecia - Companies Involved in Therapeutics Development 14
Aclaris Therapeutics Inc 14
Allergan Plc 15
Almirall SA 16
BiologicsMD Inc 17
Dong-A Socio Holdings Co Ltd 18
Histogen Inc 19
RepliCel Life Sciences Inc 20
RiverTown Therapeutics Inc 21
Samumed LLC 22
Sucampo Pharmaceuticals Inc 23
SWITCH Biotech LLC 24
Androgenic Alopecia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(cyclosporine A + minoxidil + RT-175) - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
bimatoprost - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BMD-1341 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BRM-421 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CB-0301 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
finasteride - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
finasteride - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
HGEN-001 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
RCH-01 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
RK-023 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
setipiprant - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
SM-04554 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule for Androgenic Alopecia - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Androgenic Alopecia - Dormant Projects 58
Androgenic Alopecia - Discontinued Products 59
Androgenic Alopecia - Product Development Milestones 60
Featured News & Press Releases 60
Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles 60
Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01 60
Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan 61
Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial 62
Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial 62
Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia 63
Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient 64
Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research 64
Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 65
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum 66
May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness 66
Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine 67
Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology 67
Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for Androgenic Alopecia, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Androgenic Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2016 14
Androgenic Alopecia - Pipeline by Allergan Plc, H2 2016 15
Androgenic Alopecia - Pipeline by Almirall SA, H2 2016 16
Androgenic Alopecia - Pipeline by BiologicsMD Inc, H2 2016 17
Androgenic Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 18
Androgenic Alopecia - Pipeline by Histogen Inc, H2 2016 19
Androgenic Alopecia - Pipeline by RepliCel Life Sciences Inc, H2 2016 20
Androgenic Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2016 21
Androgenic Alopecia - Pipeline by Samumed LLC, H2 2016 22
Androgenic Alopecia - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 23
Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Assessment by Combination Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Androgenic Alopecia - Dormant Projects, H2 2016 58
Androgenic Alopecia - Discontinued Products, H2 2016 59